<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>508</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15530682</PubmedId>
            <Abstract>The degree of epitope density has been shown to be a critical factor influencing the magnitude of epitope-specific responses. However, whether high epitope density in just a single protein molecule can still enhance the humoral response or, more importantly, the protective immunity, has not been determined. To test this, five glutathione-S-transferase fusion proteins bearing various numbers of copies of the M2e epitope on M2 protein of influenza virus (1, 2, 4, 8 and 16 copies) were prepared, and used to immunize mice and rabbits. Our data show clearly that M2e-specific humoral response was enhanced with increasing epitope density. By lethal challenge assay in mice, it was observed that recombinant proteins with higher M2e epitope densities resulted in higher survival rates and slower weight losses. The survival rate was directly related to the degree of epitope density in the single recombinant protein: 100% in the case of 16 M2e copies; 50% with 4 M2e epitopes; and 0% with one.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>366-71</ArticlePages>
            <ArticleTitle>High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Wanli</ForeName>
                </Author>
                <Author>
                    <LastName>Peng</LastName>
                    <ForeName>Zou</ForeName>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Zuqiang</ForeName>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Yun</ForeName>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Jian</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ying-Hua</ForeName>
                </Author>
            </Authors>
            <Affiliations>Laboratory of Immunology, Protein Science Laboratory of MOE, Department of Biology, Tsinghua University, Beijing 100084, PR China.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Epitopes;M2 protein, Influenza A virus;Recombinant Fusion Proteins;Viral Matrix Proteins;Glutathione Transferase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Viral(immunology); Epitopes; Female; Flow Cytometry; Glutathione Transferase(genetics); Immunization; In Vitro Techniques; Influenza A virus(immunology); Mice; Mice, Inbred BALB C; Models, Biological; Orthomyxoviridae Infections(immunology; mortality; prevention &amp; control); Rabbits; Recombinant Fusion Proteins(genetics; immunology); Survival Rate; Time Factors; Viral Matrix Proteins(genetics; immunology); Virus Replication</ArticleMeshHeadingsList>
            <Journal>
                <Volume>23</Volume>
                <Issue>3</Issue>
                <Title>Vaccine</Title>
                <Issn>0264-410X</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>M2e 2-24</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SLLTEVETPIRNEWGCRCNDSSD</LinearSequence>
                        <StartingPosition>2</StartingPosition>
                        <EndingPosition>24</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P10920.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>382781</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>59318</EpitopeId>
                <ReferenceStartingPosition>2</ReferenceStartingPosition>
                <ReferenceEndingPosition>24</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This peptide is representative of the extracellular domain of M2 protein as found in several strains, such as A/Singapore/1/57. For infection studies, the strains of virus used in this paper harbor differences at some residues: Wuhan/359/95: SLPTEVETPIRSEWGCRCNDSSD; PR8/34: SLLTEVETPIRNEWGCRCNGSSD. The swiss-prot ID provided here is representative of several strains that harbor this sequence in Influenza A viruses.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>4369</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SLLTEVETPIRNEWGCRCNDSSD</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>24</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P10920.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>382781</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>(M2e 1-24)&lt;sub&gt;16&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide Repeat Sequence (linear)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <DoseSchedule>3 doses 2 wks apart with 50 μg conjugate, first in CFA, boosts in IFA.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen was constructed as a fusion protein harboring 16 copies of the epitope fused to GST. Also constructs with 1 and 4 repetitions were tested. For immunization of rabbits (NZW strain), 200 μg of conjugate was given, 3 weeks apart. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This experiment utilized single and repetitive epitope constructs (polymers of 4 and 16 repeats) as immunogens, conjugated to GST, and compared humoral responses agaisnt the M2e 2-24 peptide (the sequence of the antigen in the ELISA is actually KSLLTEVETPIRNEWGCRCNDSSD). The 16-repeat construct shows higher immunogenicity, specially at the responses after 1st and  2nd immunization. Similar results were obtained for humoral responses in rabbits (Oryctolagus cuniculus).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>M2e 2-24</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SLLTEVETPIRNEWGCRCNDSSD</LinearSequence>
                                        <StartingPosition>2</StartingPosition>
                                        <EndingPosition>24</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P10920.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>382781</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>4380</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000206</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SLLTEVETPIRNEWGCRCNDSSD</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>24</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P10920.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>382781</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>(M2e 1-24)&lt;sub&gt;16&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide Repeat Sequence (linear)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <DoseSchedule>3 doses 3 weeks apart, with 200 μg/dose. First in CFA, others in IFA.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen is a recombinant fusion protein of GST and 16 repeats of M2e 2-24. Also constructs with 1 and 4 repeats were tested. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Recognition of virus-infected MDCK cells was measured. This experiment compared efficacy of sera obtained from rabbits innoculated with single and repetitive epitope constructs (polymers of 4 and 16 repeats) as immunogens. The 16-repeat construct shows higher immunogenicity.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>63106</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 5A and B, Table 2</LocationOfData>
                        <BCellId>4387</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SLLTEVETPIRNEWGCRCNDSSD</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>24</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P10920.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>382781</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>(M2e 1-24)&lt;sub&gt;16&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide Repeat Sequence (linear)</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Adjuvant>GMDP</Adjuvant>
                                <Adjuvant>Gamma Inulin</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 50 μg conjugate, first in CFA, boosts in IFA.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The immunogen is a recombinant fusion protein of GST and 16 repeats of M2e 2-24. Also constructs with 1 and 4 repeats were tested. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>124</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>100.0</QuantitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>This experiment utilized single and repetitive epitope constructs (polymers of 4 and 16 repeats) as immunogens, conjugated to GST, and compared survival rates among recipients of different constructs.  Mice were administered lethal challenge (5 LD50) i.n. with Influenza A virus (A/PR/8/34).  Constructs containing 4 and 16 copies of the epitope elicited 50% and 100% survival rates in test animals compared to single-epitope and control immunizations which did not result in animal survival. The 16 repeat  construct  also protected mice from weight loss after challenge.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Puerto Rico/8/34(H1N1))</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

